Drug Criteria & Outcomes: Drugs In the Pipeline
July 1, 2001 less than 1 minute read
Drug Criteria & Outcomes
In the Pipeline
• Myriad Genetics reports that it has begun preclinical testing of its anti-thrombin III drug (MPC-1203). The drug is used for the treatment of acute thrombotic events such as those due to inflammation following major trauma, orthopedic or open-heart surgery, as well as for the prevention of blood clotting due to sepsis and cancer.
• SciClone Pharmaceuticals announces it has initiated a Phase II trial combining the company’s immune system enhancer (Zadaxin) with transarterial chemoembolization in patients with hepatocellular carcinoma. A Phase II trial also was initiated in January that combined the drug with radio frequency ablation.
• Scios announces that that the Cardiovascular and Renal Drugs Advisory Committee to the FDA has unanimously recommended approval of nesiritide (Natrecor) for the treatment of acute congestive heart failure by a vote of 10-0. If approved by the FDA, Natrecor would be the first new treatment for acute CHF in more than a decade.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content